Pandemic Influenza Preparedness and Response 2012-2016

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a Master IDIQ on September 1, 2012 for pandemic influenza preparedness and response, with the last date to order on July 21, 2018—the vehicle is closed to new task orders as of that date. The shared ceiling is $4.7 billion.

This vehicle is no longer active for new work. Ordering closed nearly eight years ago, and the portfolio shows the last task order awarded in March 2018. The combined potential value of all 63 awarded task orders totals $256.7 million, which is fully obligated. Annual ordering peaked in 2014 at 10 orders and has declined steadily, falling to just two orders in 2018.

Task orders funded acquisition of pre-pandemic and pandemic influenza vaccines—clinical, pilot, and commercial bulk lots—along with adjuvants (particularly MF59), formulation-fill-finish services, preclinical and clinical studies, storage and stability programs for bulk and final containers, international shipping, and disposal. Orders ranged from small allocations under $50,000 to large contracts exceeding $20 million, with firm fixed price and cost-plus fixed fee structures both represented.

Novartis Vaccines and Diagnostics, Inc. dominates the vehicle, holding 17 orders worth $102.9 million combined potential value. Seqirus Inc. and Seqirus USA Inc. together hold 21 orders valued at $74.5 million. Sanofi Vaccines US Inc. holds 13 orders worth $48.8 million. Glaxosmithkline, LLC and smaller contractors round out the five distinct primes. The top four contractors account for roughly 94 percent of all task orders by count and 95 percent by potential value. All customer funding came from HHS Office of the Assistant Secretary for Preparedness and Response; no other federal agencies placed orders. All 63 task orders were unrestricted, with no set-asides applied.

In response to the circulating H5N1 avian influenza virus, the Department of Health and Human Services has awarded a Master IDIQ for the supply of the following items and/or services in accordance to the BARDA Strategic Plan (2011-2016): pre-pandemic master/working virus seeds; pre-pandemic and pandemic pilot, clinical and commercial bulk vaccines and adjuvants; storage and stability studies of vaccines and adjuvants; formulation-fill-finish of vaccine and adjuvants; preclinical and clinical studies with pre-pandemic and pandemic vaccine; international shipping; storage services and stability program for vaccine and adjuvants, (bulk and final containers) from current contracts when applicable; and disposal of vaccine bulk and final containers.